Teva closes one Canadian plant, expands two more

pharmafile | July 22, 2011 | News story | Manufacturing and Production |  Canada, Teva 

Teva Pharmaceutical has decided to shut down its recently-acquired manufacturing Canadian facility in Montreal, Quebec, having failed to find a buyer for the plant.

Quebec’s loss looks to be Ontario’s gain, however, as the generics company has also decided to expand production at two plants in Stouffville and Scarborough, thanks to CAD 6.5 million ($6.9m) in financial assistance from the state government.

Teva bought the Mirabel plant in Montreal plant in 2010 as part of its near-$5 billion acquisition of German generic manufacturer Ratiopharm and had previously said it planned to either sell or close the facility.

A total of 340 workers will lose their jobs as a result of the closure, although most will remain employed over the next few months as production at the plant winds down. A skeleton staff will also be retained to dismantle the facility.

Advertisement

Meanwhile, Teva will create 20 additional jobs and safeguard 182 jobs at Stouffville and Scarborough thanks to the investment programme, which will expand capacity as well as upgrade equipment at the two plants.

The upgrades will allow Teva to produce one billion more tablets of generic prescription drugs annually. The company currently produces more than six billion tablets per year for domestic and export markets.

Barry Fishman, president and chief executive of Teva Canada, said: “In addition to supporting highly skilled workers, our expanded plant and new equipment will enable us to increase our capacity to service the needs of patients in Ontario and across Canada”.

Teva has 1,900 employees in Canada.

Phil Taylor

Related Content

Teva announces positive results from trial of AJOVY for migraine

Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

Canada first country to authorise Pfizer vaccine in children aged 12-15

Canada has become the first country to authorise the use of Pfizer’s COVID-19 vaccine for …

The Gateway to Local Adoption Series

Latest content